Comparison of the efficacy of transurethral columnar balloon dilation of prostate and transurethral bipolar plasmakinetic resection of prostate in the treatment of small volume (≤30 mL) benign prostatic hyperplasia
10.3969/j.issn.1009-8291.2023.12.009
- VernacularTitle:经尿道柱状水囊前列腺扩开术与经尿道前列腺等离子电切术治疗小体积（≤30 mL）良性前列腺增生症的疗效比较
- Author:
Yuanyuan YANG
1
;
Zhen SONG
2
;
Lijian GAO
1
;
Shuheng ZHAO
1
;
Junmei YAO
3
;
Jing LI
1
;
Zhonghua XU
4
;
Haibin SONG
1
Author Information
1. Department of Urology, Qilu Hospital of Shandong University Dezhou Hospital, Dezhou 253000
2. Department of Pathology, Qilu Hospital of Shandong University Dezhou Hospital, Dezhou 253000
3. Operating Room, Qilu Hospital of Shandong University Dezhou Hospital, Dezhou 253000
4. Department of Urology, Qilu Hospital of Shandong University, Ji’nan 250063, China
- Publication Type:Journal Article
- Keywords:
transurethral columnar balloon dilation of prostate;
transurethral bipolar plasmakinetic resection of prostate;
small volume prostate;
sexual function;
benign prostatic hyperplasia;
urinary control
- From:
Journal of Modern Urology
2023;28(12):1046-1052
- CountryChina
- Language:Chinese
-
Abstract:
【Objective】 To explore the efficacy of transurethral columnar balloon dilation of prostate (TUCBDP) and transurethral bipolar plasmakinetic resection of prostate (TUPKP) for patients with small volume (≤30 mL) benign prostatic hyperplasia (BPH) and the effects on urinary control and sexual function. 【Methods】 Clinical data of BPH patients who underwent surgical treatment during Jun.2021 and Jan.2022 were reviewed. A total of 95 patients with prostate volume ≤30 mL and regular sexual life were selected as subjects, including 45 patients who received TUCBDP as the TUCBDP group and 50 patients who received TUPKP as the TUPKP group. The patients were followed up for 12 months, and the perioperative data and follow-up results were analyzed. 【Results】 The TUCBDP group had shorter operation time, less intraoperative blood loss, less postoperative hemoglobin loss and sodium concentration loss, shorter bladder irrigation time, lower pain score, shorter urinary tube indwelling time and shorter hospital stay than the TUPKP group (P<0.05). Twelve months after surgery, the International Prostate Symptom score (IPSS), quality of life score (QoL), residual urine volume (PVR) and maximum urine flow rate (Qmax) were significantly improved in both groups (P<0.05). The International Index of Erectile Function-5 (IIEF-5), Erection Hardness Grading Score (EHS), Sexual Function Score in Patients with Premature Ejaculation-5 (CIPE-5) score had no significant differences compared with those before surgery (P>0.05). The TUPKP group had worse ejaculation function score and ejaculation disturbance score after surgery (P<0.05), while the TUCBDP group had no significant change (P>0.05), and the two indexes were superior in the TUCBDP group than in the TUPKP group. The TUCBDP group had significantly lower complication rate than the TUPKP group (P<0.05). 【Conclusion】 TUCBDP is safe and effective in the treatment of small volume (≤30 mL) BPH, less trauma, less biochemical interference, less pain, fewer complications, and shorter course of disease. It has little effect on the ejaculation function and erectile function, and is more suitable for patients requiring retention of sexual function. It has a good application prospect in the treatment of small volume BPH.
